Caring Brands (NASDAQ:CABR) Issues Earnings Results

Caring Brands (NASDAQ:CABR) announced its quarterly earnings results on Friday. The company reported ($0.08) earnings per share for the quarter, FiscalAI reports.

Caring Brands Stock Performance

Shares of Caring Brands stock traded up $0.07 during trading hours on Friday, hitting $0.87. The company’s stock had a trading volume of 50,465 shares, compared to its average volume of 96,654. The stock has a market cap of $9.15 million and a price-to-earnings ratio of -1.18. Caring Brands has a twelve month low of $0.60 and a twelve month high of $1.84. The firm has a fifty day moving average of $1.15 and a 200-day moving average of $1.14.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Caring Brands in a report on Tuesday, September 8th. One analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, Caring Brands has an average rating of “Sell”.

Institutional Investors Weigh In On Caring Brands

A hedge fund recently bought a new position in Caring Brands stock. Susquehanna International Group LLP bought a new stake in Caring Brands, Inc. (NASDAQ:CABR) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 20,771 shares of the company’s stock, valued at approximately $26,000. Susquehanna International Group LLP owned approximately 0.20% of Caring Brands as of its most recent SEC filing.

Caring Brands Company Profile

We are a wellness consumer products company. We offer several over-the-counter, or (OTC) and cosmetic, consumer products. Our method of operation is to ensure that (1) the mechanism of action of all products is established, (2) efficacy is determined through controlled clinical trials, (3) products are protected by issued and filed patents, and (4) products have acceptable commercial stability. Prior to its Q3 2022 commercial launch in India as a treatment for vitiligo and psoriasis, Photocil was briefly launched in the United States markets from December 2022 until February 2023, however, was subsequently removed from the market due to insufficient sales resulting from the lack of a dedicated sales and marketing team.